Single center, open label, phase I study of intracranial injection of NK-92/5.28.z (HER2.taNK) cells in patients with recurrent HER2-positive glioblastoma (Quilt 3.C001) - CAR2BRAIN

Trial Profile

Single center, open label, phase I study of intracranial injection of NK-92/5.28.z (HER2.taNK) cells in patients with recurrent HER2-positive glioblastoma (Quilt 3.C001) - CAR2BRAIN

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs HER2.taNK NantKwest (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms CAR2BRAIN
  • Most Recent Events

    • 04 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top